Id3A to design NanoViricides cGMP production and laboratory facility
The facility will be constructed by renovating an existing 18,000ft² light manufacturing plant on a 4.2 acre in Shelton, US. Id3A will design the overall facility as well
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.